BRCA2 and neoplasm: The tumor assay used in this study showed that 93.9% (92/98) of patients with somatically mutated tumors, including TP53, BRCA1, BRCA2, KRAS, ARID1A, RB1, PIK3CA, STK11, FGR2, and RAD51D, were not adequately detected by Sanger sequencing and BRCA1/2 testing of clinical FFPE sections.